Oppenheimer Downgrades Tonix Pharma (TNXP) to Perform
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Oppenheimer downgraded Tonix Pharma (NASDAQ: TNXP) from Outperform to Perform.
Analyst Jay Olson commented, "TNXP announced the Ph 3 AFFIRM trial of TNX-102 SL in fibromyalgia missed the primary endpoint. As a result, management has decided to discontinue the fibromyalgia program. The company will now shift resources to focus on development of TNX-102 SL for PTSD. We view this setback as a delay to commercialization of TNX-102 SL with increased uncertainty around future cash requirements and, therefore downgrade TNXP to Perform and withdraw our price target."
Shares of Tonix Pharma closed at $0.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Downgrades Time Warner (TWX) to Neutral Following Takeover
- Jefferies Raises Price Target on FMC Technologies (FTI) After Adjusting Estimates
- Oppenheimer Raises Price Target on Microsoft (MSFT) to $65 Following 1Q Beat
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!